Abstract
This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.
Full Text
What is claimed is:
This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.
Timeline
Filed
04/09/2026Published
07/30/2026Granted
Not AvailableIPC Codes(3)
C07K 16/28:against receptors, cell surface antigens or cell surface determinants
A61K 39/00:Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N 33/53)
A61P 35/00:Antineoplastic agents